Phase 2 Mesothelioma Trial, Recruiting NCT06790082 Sponsor: Aalborg University Hospital Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT06790082
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have spots or growths in the lining of your lungs (pleura) that doctors suspect could be mesothelioma, and you have been referred for a biopsy of that area.
  • You have had or are currently having a type of scan called an FDG PET/CT scan as part of investigating the suspicious area.
  • You are considered physically and mentally well enough to take part in the study.
  • You are able to understand the information given about the study and agree to take part.
  • You are 18 years old or older.

Who may not be able to join:

  • You urgently need surgery or are in an emergency situation.
  • You have been diagnosed with another type of cancer (other than certain skin cancers or early-stage cervical cancer) and have received treatment for it within the last year.
  • You are currently pregnant or breastfeeding.
  • You are a woman who could potentially become pregnant and your pregnancy status is not confirmed — though you may still be able to join if a pregnancy test taken within 48 hours before the study scans comes back negative.
  • You are unable to have a PET/CT scan for any reason, such as weighing more than 180 kg, not being able to fit in the scanner, being unable to lie still during the scan, or having severe claustrophobia or a severe fear of needles that cannot be managed.
  • You have any other health condition or personal circumstance that the study doctor believes could affect the reliability of the study results or your ability to complete the study (confirm with trial site).
  • You have previously had an allergic reaction to the types of tracers (special substances) used in the PET/CT scans involved in this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Helle Zacho, MD, DMSc, Clinical Professor dept. of Nuclear Medicine, Aalborg University Hospital

Phone: +45 97665500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Aalborg University Hospital
Registry
ClinicalTrials.gov
Start date
29 January 2025
Est. completion
30 April 2027

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Diagnostic Performance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov